s aureus cvcc 546  (ATCC)


Bioz Verified Symbol ATCC is a verified supplier
Bioz Manufacturer Symbol ATCC manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 95

    Structured Review

    ATCC s aureus cvcc 546
    The effects of peptide ID13 on S. aureus . a The membrane depolarization, b differential gene expression, c enriched GO terms, and d KEGG pathway of ID13-treated S. aureus <t>CVCC</t> 546
    S Aureus Cvcc 546, supplied by ATCC, used in various techniques. Bioz Stars score: 95/100, based on 18 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/s aureus cvcc 546/product/ATCC
    Average 95 stars, based on 18 article reviews
    Price from $9.99 to $1999.99
    s aureus cvcc 546 - by Bioz Stars, 2022-11
    95/100 stars

    Images

    1) Product Images from "Therapeutic potential of a designed CSαβ peptide ID13 in Staphylococcus aureus-induced endometritis of mice"

    Article Title: Therapeutic potential of a designed CSαβ peptide ID13 in Staphylococcus aureus-induced endometritis of mice

    Journal: Applied Microbiology and Biotechnology

    doi: 10.1007/s00253-020-10685-x

    The effects of peptide ID13 on S. aureus . a The membrane depolarization, b differential gene expression, c enriched GO terms, and d KEGG pathway of ID13-treated S. aureus CVCC 546
    Figure Legend Snippet: The effects of peptide ID13 on S. aureus . a The membrane depolarization, b differential gene expression, c enriched GO terms, and d KEGG pathway of ID13-treated S. aureus CVCC 546

    Techniques Used: Expressing

    In vitro efficacy of peptide ID13.  a  Combined application of peptide ID13 with antibiotics against  S. aureus  CVCC 546, vancomycin, ampicillin, rifampin, and ciprofloxacin that are represented by Van, Amp, Rif, and Cip, respectively, and  b  antimicrobial activity against intracellular  S. aureus  CVCC 546. Inhibition of LTA-induced cytokines  c  TNF-α,  d  IL-1β,  e  IL-6, and  f  IL-10 from RAW 264.7. Statistical significance of differences between experimental and LTA groups were determined using the one-way ANOVA and Dunnett’s multiple comparison. * p
    Figure Legend Snippet: In vitro efficacy of peptide ID13. a Combined application of peptide ID13 with antibiotics against S. aureus CVCC 546, vancomycin, ampicillin, rifampin, and ciprofloxacin that are represented by Van, Amp, Rif, and Cip, respectively, and b antimicrobial activity against intracellular S. aureus CVCC 546. Inhibition of LTA-induced cytokines c TNF-α, d IL-1β, e IL-6, and f IL-10 from RAW 264.7. Statistical significance of differences between experimental and LTA groups were determined using the one-way ANOVA and Dunnett’s multiple comparison. * p

    Techniques Used: In Vitro, Activity Assay, Inhibition

    2) Product Images from "Therapeutic potential of a designed CSαβ peptide ID13 in Staphylococcus aureus-induced endometritis of mice"

    Article Title: Therapeutic potential of a designed CSαβ peptide ID13 in Staphylococcus aureus-induced endometritis of mice

    Journal: Applied Microbiology and Biotechnology

    doi: 10.1007/s00253-020-10685-x

    The effects of peptide ID13 on S. aureus . a The membrane depolarization, b differential gene expression, c enriched GO terms, and d KEGG pathway of ID13-treated S. aureus CVCC 546
    Figure Legend Snippet: The effects of peptide ID13 on S. aureus . a The membrane depolarization, b differential gene expression, c enriched GO terms, and d KEGG pathway of ID13-treated S. aureus CVCC 546

    Techniques Used: Expressing

    In vitro efficacy of peptide ID13.  a  Combined application of peptide ID13 with antibiotics against  S. aureus  CVCC 546, vancomycin, ampicillin, rifampin, and ciprofloxacin that are represented by Van, Amp, Rif, and Cip, respectively, and  b  antimicrobial activity against intracellular  S. aureus  CVCC 546. Inhibition of LTA-induced cytokines  c  TNF-α,  d  IL-1β,  e  IL-6, and  f  IL-10 from RAW 264.7. Statistical significance of differences between experimental and LTA groups were determined using the one-way ANOVA and Dunnett’s multiple comparison. * p
    Figure Legend Snippet: In vitro efficacy of peptide ID13. a Combined application of peptide ID13 with antibiotics against S. aureus CVCC 546, vancomycin, ampicillin, rifampin, and ciprofloxacin that are represented by Van, Amp, Rif, and Cip, respectively, and b antimicrobial activity against intracellular S. aureus CVCC 546. Inhibition of LTA-induced cytokines c TNF-α, d IL-1β, e IL-6, and f IL-10 from RAW 264.7. Statistical significance of differences between experimental and LTA groups were determined using the one-way ANOVA and Dunnett’s multiple comparison. * p

    Techniques Used: In Vitro, Activity Assay, Inhibition

    3) Product Images from "Therapeutic potential of a designed CSαβ peptide ID13 in Staphylococcus aureus-induced endometritis of mice"

    Article Title: Therapeutic potential of a designed CSαβ peptide ID13 in Staphylococcus aureus-induced endometritis of mice

    Journal: Applied Microbiology and Biotechnology

    doi: 10.1007/s00253-020-10685-x

    The effects of peptide ID13 on S. aureus . a The membrane depolarization, b differential gene expression, c enriched GO terms, and d KEGG pathway of ID13-treated S. aureus CVCC 546
    Figure Legend Snippet: The effects of peptide ID13 on S. aureus . a The membrane depolarization, b differential gene expression, c enriched GO terms, and d KEGG pathway of ID13-treated S. aureus CVCC 546

    Techniques Used: Expressing

    In vitro efficacy of peptide ID13.  a  Combined application of peptide ID13 with antibiotics against  S. aureus  CVCC 546, vancomycin, ampicillin, rifampin, and ciprofloxacin that are represented by Van, Amp, Rif, and Cip, respectively, and  b  antimicrobial activity against intracellular  S. aureus  CVCC 546. Inhibition of LTA-induced cytokines  c  TNF-α,  d  IL-1β,  e  IL-6, and  f  IL-10 from RAW 264.7. Statistical significance of differences between experimental and LTA groups were determined using the one-way ANOVA and Dunnett’s multiple comparison. * p
    Figure Legend Snippet: In vitro efficacy of peptide ID13. a Combined application of peptide ID13 with antibiotics against S. aureus CVCC 546, vancomycin, ampicillin, rifampin, and ciprofloxacin that are represented by Van, Amp, Rif, and Cip, respectively, and b antimicrobial activity against intracellular S. aureus CVCC 546. Inhibition of LTA-induced cytokines c TNF-α, d IL-1β, e IL-6, and f IL-10 from RAW 264.7. Statistical significance of differences between experimental and LTA groups were determined using the one-way ANOVA and Dunnett’s multiple comparison. * p

    Techniques Used: In Vitro, Activity Assay, Inhibition

    4) Product Images from "Therapeutic potential of a designed CSαβ peptide ID13 in Staphylococcus aureus-induced endometritis of mice"

    Article Title: Therapeutic potential of a designed CSαβ peptide ID13 in Staphylococcus aureus-induced endometritis of mice

    Journal: Applied Microbiology and Biotechnology

    doi: 10.1007/s00253-020-10685-x

    The effects of peptide ID13 on S. aureus . a The membrane depolarization, b differential gene expression, c enriched GO terms, and d KEGG pathway of ID13-treated S. aureus CVCC 546
    Figure Legend Snippet: The effects of peptide ID13 on S. aureus . a The membrane depolarization, b differential gene expression, c enriched GO terms, and d KEGG pathway of ID13-treated S. aureus CVCC 546

    Techniques Used: Expressing

    In vitro efficacy of peptide ID13.  a  Combined application of peptide ID13 with antibiotics against  S. aureus  CVCC 546, vancomycin, ampicillin, rifampin, and ciprofloxacin that are represented by Van, Amp, Rif, and Cip, respectively, and  b  antimicrobial activity against intracellular  S. aureus  CVCC 546. Inhibition of LTA-induced cytokines  c  TNF-α,  d  IL-1β,  e  IL-6, and  f  IL-10 from RAW 264.7. Statistical significance of differences between experimental and LTA groups were determined using the one-way ANOVA and Dunnett’s multiple comparison. * p
    Figure Legend Snippet: In vitro efficacy of peptide ID13. a Combined application of peptide ID13 with antibiotics against S. aureus CVCC 546, vancomycin, ampicillin, rifampin, and ciprofloxacin that are represented by Van, Amp, Rif, and Cip, respectively, and b antimicrobial activity against intracellular S. aureus CVCC 546. Inhibition of LTA-induced cytokines c TNF-α, d IL-1β, e IL-6, and f IL-10 from RAW 264.7. Statistical significance of differences between experimental and LTA groups were determined using the one-way ANOVA and Dunnett’s multiple comparison. * p

    Techniques Used: In Vitro, Activity Assay, Inhibition

    5) Product Images from "Therapeutic potential of a designed CSαβ peptide ID13 in Staphylococcus aureus-induced endometritis of mice"

    Article Title: Therapeutic potential of a designed CSαβ peptide ID13 in Staphylococcus aureus-induced endometritis of mice

    Journal: Applied Microbiology and Biotechnology

    doi: 10.1007/s00253-020-10685-x

    The effects of peptide ID13 on S. aureus . a The membrane depolarization, b differential gene expression, c enriched GO terms, and d KEGG pathway of ID13-treated S. aureus CVCC 546
    Figure Legend Snippet: The effects of peptide ID13 on S. aureus . a The membrane depolarization, b differential gene expression, c enriched GO terms, and d KEGG pathway of ID13-treated S. aureus CVCC 546

    Techniques Used: Expressing

    In vitro efficacy of peptide ID13.  a  Combined application of peptide ID13 with antibiotics against  S. aureus  CVCC 546, vancomycin, ampicillin, rifampin, and ciprofloxacin that are represented by Van, Amp, Rif, and Cip, respectively, and  b  antimicrobial activity against intracellular  S. aureus  CVCC 546. Inhibition of LTA-induced cytokines  c  TNF-α,  d  IL-1β,  e  IL-6, and  f  IL-10 from RAW 264.7. Statistical significance of differences between experimental and LTA groups were determined using the one-way ANOVA and Dunnett’s multiple comparison. * p
    Figure Legend Snippet: In vitro efficacy of peptide ID13. a Combined application of peptide ID13 with antibiotics against S. aureus CVCC 546, vancomycin, ampicillin, rifampin, and ciprofloxacin that are represented by Van, Amp, Rif, and Cip, respectively, and b antimicrobial activity against intracellular S. aureus CVCC 546. Inhibition of LTA-induced cytokines c TNF-α, d IL-1β, e IL-6, and f IL-10 from RAW 264.7. Statistical significance of differences between experimental and LTA groups were determined using the one-way ANOVA and Dunnett’s multiple comparison. * p

    Techniques Used: In Vitro, Activity Assay, Inhibition

    6) Product Images from "Therapeutic potential of a designed CSαβ peptide ID13 in Staphylococcus aureus-induced endometritis of mice"

    Article Title: Therapeutic potential of a designed CSαβ peptide ID13 in Staphylococcus aureus-induced endometritis of mice

    Journal: Applied Microbiology and Biotechnology

    doi: 10.1007/s00253-020-10685-x

    The effects of peptide ID13 on S. aureus . a The membrane depolarization, b differential gene expression, c enriched GO terms, and d KEGG pathway of ID13-treated S. aureus CVCC 546
    Figure Legend Snippet: The effects of peptide ID13 on S. aureus . a The membrane depolarization, b differential gene expression, c enriched GO terms, and d KEGG pathway of ID13-treated S. aureus CVCC 546

    Techniques Used: Expressing

    In vitro efficacy of peptide ID13.  a  Combined application of peptide ID13 with antibiotics against  S. aureus  CVCC 546, vancomycin, ampicillin, rifampin, and ciprofloxacin that are represented by Van, Amp, Rif, and Cip, respectively, and  b  antimicrobial activity against intracellular  S. aureus  CVCC 546. Inhibition of LTA-induced cytokines  c  TNF-α,  d  IL-1β,  e  IL-6, and  f  IL-10 from RAW 264.7. Statistical significance of differences between experimental and LTA groups were determined using the one-way ANOVA and Dunnett’s multiple comparison. * p
    Figure Legend Snippet: In vitro efficacy of peptide ID13. a Combined application of peptide ID13 with antibiotics against S. aureus CVCC 546, vancomycin, ampicillin, rifampin, and ciprofloxacin that are represented by Van, Amp, Rif, and Cip, respectively, and b antimicrobial activity against intracellular S. aureus CVCC 546. Inhibition of LTA-induced cytokines c TNF-α, d IL-1β, e IL-6, and f IL-10 from RAW 264.7. Statistical significance of differences between experimental and LTA groups were determined using the one-way ANOVA and Dunnett’s multiple comparison. * p

    Techniques Used: In Vitro, Activity Assay, Inhibition

    7) Product Images from "Therapeutic potential of a designed CSαβ peptide ID13 in Staphylococcus aureus-induced endometritis of mice"

    Article Title: Therapeutic potential of a designed CSαβ peptide ID13 in Staphylococcus aureus-induced endometritis of mice

    Journal: Applied Microbiology and Biotechnology

    doi: 10.1007/s00253-020-10685-x

    The effects of peptide ID13 on S. aureus . a The membrane depolarization, b differential gene expression, c enriched GO terms, and d KEGG pathway of ID13-treated S. aureus CVCC 546
    Figure Legend Snippet: The effects of peptide ID13 on S. aureus . a The membrane depolarization, b differential gene expression, c enriched GO terms, and d KEGG pathway of ID13-treated S. aureus CVCC 546

    Techniques Used: Expressing

    In vitro efficacy of peptide ID13.  a  Combined application of peptide ID13 with antibiotics against  S. aureus  CVCC 546, vancomycin, ampicillin, rifampin, and ciprofloxacin that are represented by Van, Amp, Rif, and Cip, respectively, and  b  antimicrobial activity against intracellular  S. aureus  CVCC 546. Inhibition of LTA-induced cytokines  c  TNF-α,  d  IL-1β,  e  IL-6, and  f  IL-10 from RAW 264.7. Statistical significance of differences between experimental and LTA groups were determined using the one-way ANOVA and Dunnett’s multiple comparison. * p
    Figure Legend Snippet: In vitro efficacy of peptide ID13. a Combined application of peptide ID13 with antibiotics against S. aureus CVCC 546, vancomycin, ampicillin, rifampin, and ciprofloxacin that are represented by Van, Amp, Rif, and Cip, respectively, and b antimicrobial activity against intracellular S. aureus CVCC 546. Inhibition of LTA-induced cytokines c TNF-α, d IL-1β, e IL-6, and f IL-10 from RAW 264.7. Statistical significance of differences between experimental and LTA groups were determined using the one-way ANOVA and Dunnett’s multiple comparison. * p

    Techniques Used: In Vitro, Activity Assay, Inhibition

    8) Product Images from "Therapeutic potential of a designed CSαβ peptide ID13 in Staphylococcus aureus-induced endometritis of mice"

    Article Title: Therapeutic potential of a designed CSαβ peptide ID13 in Staphylococcus aureus-induced endometritis of mice

    Journal: Applied Microbiology and Biotechnology

    doi: 10.1007/s00253-020-10685-x

    The effects of peptide ID13 on S. aureus . a The membrane depolarization, b differential gene expression, c enriched GO terms, and d KEGG pathway of ID13-treated S. aureus CVCC 546
    Figure Legend Snippet: The effects of peptide ID13 on S. aureus . a The membrane depolarization, b differential gene expression, c enriched GO terms, and d KEGG pathway of ID13-treated S. aureus CVCC 546

    Techniques Used: Expressing

    In vitro efficacy of peptide ID13.  a  Combined application of peptide ID13 with antibiotics against  S. aureus  CVCC 546, vancomycin, ampicillin, rifampin, and ciprofloxacin that are represented by Van, Amp, Rif, and Cip, respectively, and  b  antimicrobial activity against intracellular  S. aureus  CVCC 546. Inhibition of LTA-induced cytokines  c  TNF-α,  d  IL-1β,  e  IL-6, and  f  IL-10 from RAW 264.7. Statistical significance of differences between experimental and LTA groups were determined using the one-way ANOVA and Dunnett’s multiple comparison. * p
    Figure Legend Snippet: In vitro efficacy of peptide ID13. a Combined application of peptide ID13 with antibiotics against S. aureus CVCC 546, vancomycin, ampicillin, rifampin, and ciprofloxacin that are represented by Van, Amp, Rif, and Cip, respectively, and b antimicrobial activity against intracellular S. aureus CVCC 546. Inhibition of LTA-induced cytokines c TNF-α, d IL-1β, e IL-6, and f IL-10 from RAW 264.7. Statistical significance of differences between experimental and LTA groups were determined using the one-way ANOVA and Dunnett’s multiple comparison. * p

    Techniques Used: In Vitro, Activity Assay, Inhibition

    9) Product Images from "Therapeutic potential of a designed CSαβ peptide ID13 in Staphylococcus aureus-induced endometritis of mice"

    Article Title: Therapeutic potential of a designed CSαβ peptide ID13 in Staphylococcus aureus-induced endometritis of mice

    Journal: Applied Microbiology and Biotechnology

    doi: 10.1007/s00253-020-10685-x

    The effects of peptide ID13 on S. aureus . a The membrane depolarization, b differential gene expression, c enriched GO terms, and d KEGG pathway of ID13-treated S. aureus CVCC 546
    Figure Legend Snippet: The effects of peptide ID13 on S. aureus . a The membrane depolarization, b differential gene expression, c enriched GO terms, and d KEGG pathway of ID13-treated S. aureus CVCC 546

    Techniques Used: Expressing

    In vitro efficacy of peptide ID13.  a  Combined application of peptide ID13 with antibiotics against  S. aureus  CVCC 546, vancomycin, ampicillin, rifampin, and ciprofloxacin that are represented by Van, Amp, Rif, and Cip, respectively, and  b  antimicrobial activity against intracellular  S. aureus  CVCC 546. Inhibition of LTA-induced cytokines  c  TNF-α,  d  IL-1β,  e  IL-6, and  f  IL-10 from RAW 264.7. Statistical significance of differences between experimental and LTA groups were determined using the one-way ANOVA and Dunnett’s multiple comparison. * p
    Figure Legend Snippet: In vitro efficacy of peptide ID13. a Combined application of peptide ID13 with antibiotics against S. aureus CVCC 546, vancomycin, ampicillin, rifampin, and ciprofloxacin that are represented by Van, Amp, Rif, and Cip, respectively, and b antimicrobial activity against intracellular S. aureus CVCC 546. Inhibition of LTA-induced cytokines c TNF-α, d IL-1β, e IL-6, and f IL-10 from RAW 264.7. Statistical significance of differences between experimental and LTA groups were determined using the one-way ANOVA and Dunnett’s multiple comparison. * p

    Techniques Used: In Vitro, Activity Assay, Inhibition

    10) Product Images from "Therapeutic potential of a designed CSαβ peptide ID13 in Staphylococcus aureus-induced endometritis of mice"

    Article Title: Therapeutic potential of a designed CSαβ peptide ID13 in Staphylococcus aureus-induced endometritis of mice

    Journal: Applied Microbiology and Biotechnology

    doi: 10.1007/s00253-020-10685-x

    The effects of peptide ID13 on S. aureus . a The membrane depolarization, b differential gene expression, c enriched GO terms, and d KEGG pathway of ID13-treated S. aureus CVCC 546
    Figure Legend Snippet: The effects of peptide ID13 on S. aureus . a The membrane depolarization, b differential gene expression, c enriched GO terms, and d KEGG pathway of ID13-treated S. aureus CVCC 546

    Techniques Used: Expressing

    In vitro efficacy of peptide ID13.  a  Combined application of peptide ID13 with antibiotics against  S. aureus  CVCC 546, vancomycin, ampicillin, rifampin, and ciprofloxacin that are represented by Van, Amp, Rif, and Cip, respectively, and  b  antimicrobial activity against intracellular  S. aureus  CVCC 546. Inhibition of LTA-induced cytokines  c  TNF-α,  d  IL-1β,  e  IL-6, and  f  IL-10 from RAW 264.7. Statistical significance of differences between experimental and LTA groups were determined using the one-way ANOVA and Dunnett’s multiple comparison. * p
    Figure Legend Snippet: In vitro efficacy of peptide ID13. a Combined application of peptide ID13 with antibiotics against S. aureus CVCC 546, vancomycin, ampicillin, rifampin, and ciprofloxacin that are represented by Van, Amp, Rif, and Cip, respectively, and b antimicrobial activity against intracellular S. aureus CVCC 546. Inhibition of LTA-induced cytokines c TNF-α, d IL-1β, e IL-6, and f IL-10 from RAW 264.7. Statistical significance of differences between experimental and LTA groups were determined using the one-way ANOVA and Dunnett’s multiple comparison. * p

    Techniques Used: In Vitro, Activity Assay, Inhibition

    11) Product Images from "An Enhanced Variant Designed From DLP4 Cationic Peptide Against Staphylococcus aureus CVCC 546"

    Article Title: An Enhanced Variant Designed From DLP4 Cationic Peptide Against Staphylococcus aureus CVCC 546

    Journal: Frontiers in Microbiology

    doi: 10.3389/fmicb.2020.01057

    The binding of ID13 and DLP4 to S. aureus CVCC 546 gDNA. (A) Gel retardation analysis of the binding of ID13 and DLP4 to S. aureus CVCC 546 gDNA at peptide/gDNA mass ratios of 0, 0.5, 1, 2.5, and 5, respectively. M: λDNA/Hind III marker. (B) Atomic force microscopy (AFM) analysis of the binding of ID13 and DLP4 to S. aureus CVCC 546 gDNA. (C) CD spectra of S. aureus CVCC 546 gDNA at peptide/gDNA mass ratios of 0, 0.5, and 1, respectively.
    Figure Legend Snippet: The binding of ID13 and DLP4 to S. aureus CVCC 546 gDNA. (A) Gel retardation analysis of the binding of ID13 and DLP4 to S. aureus CVCC 546 gDNA at peptide/gDNA mass ratios of 0, 0.5, 1, 2.5, and 5, respectively. M: λDNA/Hind III marker. (B) Atomic force microscopy (AFM) analysis of the binding of ID13 and DLP4 to S. aureus CVCC 546 gDNA. (C) CD spectra of S. aureus CVCC 546 gDNA at peptide/gDNA mass ratios of 0, 0.5, and 1, respectively.

    Techniques Used: Binding Assay, Electrophoretic Mobility Shift Assay, Marker, Microscopy

    (A) Flow cytometric analysis of S. aureus CVCC 546. Cells were treated with 1×, 2×, or 4 × MIC ID13, respectively; cells treated with 2 × MIC DLP4 or vancomycin (Van) and left without treatment were used as the positive and negative control, respectively ( n = 3). (B) The extracellular levels of K + released by S. aureus CVCC 546 cells treated with peptide ID13, DLP4, and nisin, respectively ( n = 3). Statistical significance of differences was determined using (A) one-way and (B) two-way ANOVA followed by Dunnett’s multiple comparison. **** p
    Figure Legend Snippet: (A) Flow cytometric analysis of S. aureus CVCC 546. Cells were treated with 1×, 2×, or 4 × MIC ID13, respectively; cells treated with 2 × MIC DLP4 or vancomycin (Van) and left without treatment were used as the positive and negative control, respectively ( n = 3). (B) The extracellular levels of K + released by S. aureus CVCC 546 cells treated with peptide ID13, DLP4, and nisin, respectively ( n = 3). Statistical significance of differences was determined using (A) one-way and (B) two-way ANOVA followed by Dunnett’s multiple comparison. **** p

    Techniques Used: Negative Control

    (A) SEM and (B) TEM micrographs of S. aureus CVCC 546 treated with ID13, DLP4, or vancomycin (Van) at 4 × MIC for 2 h or left untreated as control. Red arrow: membrane perforation; yellow arrow: cell shrinkage; green arrow: leakage of cytosol; blue arrow: empty regions; cyan arrow: mesosome-like structure; black arrow: cell rupture.
    Figure Legend Snippet: (A) SEM and (B) TEM micrographs of S. aureus CVCC 546 treated with ID13, DLP4, or vancomycin (Van) at 4 × MIC for 2 h or left untreated as control. Red arrow: membrane perforation; yellow arrow: cell shrinkage; green arrow: leakage of cytosol; blue arrow: empty regions; cyan arrow: mesosome-like structure; black arrow: cell rupture.

    Techniques Used: Transmission Electron Microscopy

    The efficacy of peptide ID13 in vitro and in vivo with DLP4 and vancomycin (Van) as positive controls. (A) Time-kill assay of ID13, DLP4, and vancomycin (Van) against S. aureus CVCC 546 ( n = 3). (B) PAEs of ID13, DLP4, and vancomycin (Van) against S. aureus CVCC 546 ( n = 3). (C) Single i.p. treatment with ID13, DLP4, and vancomycin (Van) in the mouse thigh infection model ( n = 6). Effects of ID13, DLP4, and vancomycin (Van) on inflammatory cytokine levels of (D) TNF-α, (E) IL-6, and (F) IL-10. Statistical significance of differences was determined using the two-way ANOVA for (A) and one-way ANOVA for (B–F) , followed by Dunnett’s multiple comparison. (*) indicates the significance between ID13, DLP4, or vancomycin and PBS. ** p
    Figure Legend Snippet: The efficacy of peptide ID13 in vitro and in vivo with DLP4 and vancomycin (Van) as positive controls. (A) Time-kill assay of ID13, DLP4, and vancomycin (Van) against S. aureus CVCC 546 ( n = 3). (B) PAEs of ID13, DLP4, and vancomycin (Van) against S. aureus CVCC 546 ( n = 3). (C) Single i.p. treatment with ID13, DLP4, and vancomycin (Van) in the mouse thigh infection model ( n = 6). Effects of ID13, DLP4, and vancomycin (Van) on inflammatory cytokine levels of (D) TNF-α, (E) IL-6, and (F) IL-10. Statistical significance of differences was determined using the two-way ANOVA for (A) and one-way ANOVA for (B–F) , followed by Dunnett’s multiple comparison. (*) indicates the significance between ID13, DLP4, or vancomycin and PBS. ** p

    Techniques Used: In Vitro, In Vivo, Time-Kill Assay, Infection

    12) Product Images from "An Enhanced Variant Designed From DLP4 Cationic Peptide Against Staphylococcus aureus CVCC 546"

    Article Title: An Enhanced Variant Designed From DLP4 Cationic Peptide Against Staphylococcus aureus CVCC 546

    Journal: Frontiers in Microbiology

    doi: 10.3389/fmicb.2020.01057

    The binding of ID13 and DLP4 to S. aureus CVCC 546 gDNA. (A) Gel retardation analysis of the binding of ID13 and DLP4 to S. aureus CVCC 546 gDNA at peptide/gDNA mass ratios of 0, 0.5, 1, 2.5, and 5, respectively. M: λDNA/Hind III marker. (B) Atomic force microscopy (AFM) analysis of the binding of ID13 and DLP4 to S. aureus CVCC 546 gDNA. (C) CD spectra of S. aureus CVCC 546 gDNA at peptide/gDNA mass ratios of 0, 0.5, and 1, respectively.
    Figure Legend Snippet: The binding of ID13 and DLP4 to S. aureus CVCC 546 gDNA. (A) Gel retardation analysis of the binding of ID13 and DLP4 to S. aureus CVCC 546 gDNA at peptide/gDNA mass ratios of 0, 0.5, 1, 2.5, and 5, respectively. M: λDNA/Hind III marker. (B) Atomic force microscopy (AFM) analysis of the binding of ID13 and DLP4 to S. aureus CVCC 546 gDNA. (C) CD spectra of S. aureus CVCC 546 gDNA at peptide/gDNA mass ratios of 0, 0.5, and 1, respectively.

    Techniques Used: Binding Assay, Electrophoretic Mobility Shift Assay, Marker, Microscopy

    (A) Flow cytometric analysis of S. aureus CVCC 546. Cells were treated with 1×, 2×, or 4 × MIC ID13, respectively; cells treated with 2 × MIC DLP4 or vancomycin (Van) and left without treatment were used as the positive and negative control, respectively ( n = 3). (B) The extracellular levels of K + released by S. aureus CVCC 546 cells treated with peptide ID13, DLP4, and nisin, respectively ( n = 3). Statistical significance of differences was determined using (A) one-way and (B) two-way ANOVA followed by Dunnett’s multiple comparison. **** p
    Figure Legend Snippet: (A) Flow cytometric analysis of S. aureus CVCC 546. Cells were treated with 1×, 2×, or 4 × MIC ID13, respectively; cells treated with 2 × MIC DLP4 or vancomycin (Van) and left without treatment were used as the positive and negative control, respectively ( n = 3). (B) The extracellular levels of K + released by S. aureus CVCC 546 cells treated with peptide ID13, DLP4, and nisin, respectively ( n = 3). Statistical significance of differences was determined using (A) one-way and (B) two-way ANOVA followed by Dunnett’s multiple comparison. **** p

    Techniques Used: Negative Control

    (A) SEM and (B) TEM micrographs of S. aureus CVCC 546 treated with ID13, DLP4, or vancomycin (Van) at 4 × MIC for 2 h or left untreated as control. Red arrow: membrane perforation; yellow arrow: cell shrinkage; green arrow: leakage of cytosol; blue arrow: empty regions; cyan arrow: mesosome-like structure; black arrow: cell rupture.
    Figure Legend Snippet: (A) SEM and (B) TEM micrographs of S. aureus CVCC 546 treated with ID13, DLP4, or vancomycin (Van) at 4 × MIC for 2 h or left untreated as control. Red arrow: membrane perforation; yellow arrow: cell shrinkage; green arrow: leakage of cytosol; blue arrow: empty regions; cyan arrow: mesosome-like structure; black arrow: cell rupture.

    Techniques Used: Transmission Electron Microscopy

    The efficacy of peptide ID13 in vitro and in vivo with DLP4 and vancomycin (Van) as positive controls. (A) Time-kill assay of ID13, DLP4, and vancomycin (Van) against S. aureus CVCC 546 ( n = 3). (B) PAEs of ID13, DLP4, and vancomycin (Van) against S. aureus CVCC 546 ( n = 3). (C) Single i.p. treatment with ID13, DLP4, and vancomycin (Van) in the mouse thigh infection model ( n = 6). Effects of ID13, DLP4, and vancomycin (Van) on inflammatory cytokine levels of (D) TNF-α, (E) IL-6, and (F) IL-10. Statistical significance of differences was determined using the two-way ANOVA for (A) and one-way ANOVA for (B–F) , followed by Dunnett’s multiple comparison. (*) indicates the significance between ID13, DLP4, or vancomycin and PBS. ** p
    Figure Legend Snippet: The efficacy of peptide ID13 in vitro and in vivo with DLP4 and vancomycin (Van) as positive controls. (A) Time-kill assay of ID13, DLP4, and vancomycin (Van) against S. aureus CVCC 546 ( n = 3). (B) PAEs of ID13, DLP4, and vancomycin (Van) against S. aureus CVCC 546 ( n = 3). (C) Single i.p. treatment with ID13, DLP4, and vancomycin (Van) in the mouse thigh infection model ( n = 6). Effects of ID13, DLP4, and vancomycin (Van) on inflammatory cytokine levels of (D) TNF-α, (E) IL-6, and (F) IL-10. Statistical significance of differences was determined using the two-way ANOVA for (A) and one-way ANOVA for (B–F) , followed by Dunnett’s multiple comparison. (*) indicates the significance between ID13, DLP4, or vancomycin and PBS. ** p

    Techniques Used: In Vitro, In Vivo, Time-Kill Assay, Infection

    13) Product Images from "An Enhanced Variant Designed From DLP4 Cationic Peptide Against Staphylococcus aureus CVCC 546"

    Article Title: An Enhanced Variant Designed From DLP4 Cationic Peptide Against Staphylococcus aureus CVCC 546

    Journal: Frontiers in Microbiology

    doi: 10.3389/fmicb.2020.01057

    The binding of ID13 and DLP4 to S. aureus CVCC 546 gDNA. (A) Gel retardation analysis of the binding of ID13 and DLP4 to S. aureus CVCC 546 gDNA at peptide/gDNA mass ratios of 0, 0.5, 1, 2.5, and 5, respectively. M: λDNA/Hind III marker. (B) Atomic force microscopy (AFM) analysis of the binding of ID13 and DLP4 to S. aureus CVCC 546 gDNA. (C) CD spectra of S. aureus CVCC 546 gDNA at peptide/gDNA mass ratios of 0, 0.5, and 1, respectively.
    Figure Legend Snippet: The binding of ID13 and DLP4 to S. aureus CVCC 546 gDNA. (A) Gel retardation analysis of the binding of ID13 and DLP4 to S. aureus CVCC 546 gDNA at peptide/gDNA mass ratios of 0, 0.5, 1, 2.5, and 5, respectively. M: λDNA/Hind III marker. (B) Atomic force microscopy (AFM) analysis of the binding of ID13 and DLP4 to S. aureus CVCC 546 gDNA. (C) CD spectra of S. aureus CVCC 546 gDNA at peptide/gDNA mass ratios of 0, 0.5, and 1, respectively.

    Techniques Used: Binding Assay, Electrophoretic Mobility Shift Assay, Marker, Microscopy

    (A) Flow cytometric analysis of S. aureus CVCC 546. Cells were treated with 1×, 2×, or 4 × MIC ID13, respectively; cells treated with 2 × MIC DLP4 or vancomycin (Van) and left without treatment were used as the positive and negative control, respectively ( n = 3). (B) The extracellular levels of K + released by S. aureus CVCC 546 cells treated with peptide ID13, DLP4, and nisin, respectively ( n = 3). Statistical significance of differences was determined using (A) one-way and (B) two-way ANOVA followed by Dunnett’s multiple comparison. **** p
    Figure Legend Snippet: (A) Flow cytometric analysis of S. aureus CVCC 546. Cells were treated with 1×, 2×, or 4 × MIC ID13, respectively; cells treated with 2 × MIC DLP4 or vancomycin (Van) and left without treatment were used as the positive and negative control, respectively ( n = 3). (B) The extracellular levels of K + released by S. aureus CVCC 546 cells treated with peptide ID13, DLP4, and nisin, respectively ( n = 3). Statistical significance of differences was determined using (A) one-way and (B) two-way ANOVA followed by Dunnett’s multiple comparison. **** p

    Techniques Used: Negative Control

    (A) SEM and (B) TEM micrographs of S. aureus CVCC 546 treated with ID13, DLP4, or vancomycin (Van) at 4 × MIC for 2 h or left untreated as control. Red arrow: membrane perforation; yellow arrow: cell shrinkage; green arrow: leakage of cytosol; blue arrow: empty regions; cyan arrow: mesosome-like structure; black arrow: cell rupture.
    Figure Legend Snippet: (A) SEM and (B) TEM micrographs of S. aureus CVCC 546 treated with ID13, DLP4, or vancomycin (Van) at 4 × MIC for 2 h or left untreated as control. Red arrow: membrane perforation; yellow arrow: cell shrinkage; green arrow: leakage of cytosol; blue arrow: empty regions; cyan arrow: mesosome-like structure; black arrow: cell rupture.

    Techniques Used: Transmission Electron Microscopy

    The efficacy of peptide ID13 in vitro and in vivo with DLP4 and vancomycin (Van) as positive controls. (A) Time-kill assay of ID13, DLP4, and vancomycin (Van) against S. aureus CVCC 546 ( n = 3). (B) PAEs of ID13, DLP4, and vancomycin (Van) against S. aureus CVCC 546 ( n = 3). (C) Single i.p. treatment with ID13, DLP4, and vancomycin (Van) in the mouse thigh infection model ( n = 6). Effects of ID13, DLP4, and vancomycin (Van) on inflammatory cytokine levels of (D) TNF-α, (E) IL-6, and (F) IL-10. Statistical significance of differences was determined using the two-way ANOVA for (A) and one-way ANOVA for (B–F) , followed by Dunnett’s multiple comparison. (*) indicates the significance between ID13, DLP4, or vancomycin and PBS. ** p
    Figure Legend Snippet: The efficacy of peptide ID13 in vitro and in vivo with DLP4 and vancomycin (Van) as positive controls. (A) Time-kill assay of ID13, DLP4, and vancomycin (Van) against S. aureus CVCC 546 ( n = 3). (B) PAEs of ID13, DLP4, and vancomycin (Van) against S. aureus CVCC 546 ( n = 3). (C) Single i.p. treatment with ID13, DLP4, and vancomycin (Van) in the mouse thigh infection model ( n = 6). Effects of ID13, DLP4, and vancomycin (Van) on inflammatory cytokine levels of (D) TNF-α, (E) IL-6, and (F) IL-10. Statistical significance of differences was determined using the two-way ANOVA for (A) and one-way ANOVA for (B–F) , followed by Dunnett’s multiple comparison. (*) indicates the significance between ID13, DLP4, or vancomycin and PBS. ** p

    Techniques Used: In Vitro, In Vivo, Time-Kill Assay, Infection

    14) Product Images from "An Enhanced Variant Designed From DLP4 Cationic Peptide Against Staphylococcus aureus CVCC 546"

    Article Title: An Enhanced Variant Designed From DLP4 Cationic Peptide Against Staphylococcus aureus CVCC 546

    Journal: Frontiers in Microbiology

    doi: 10.3389/fmicb.2020.01057

    The binding of ID13 and DLP4 to S. aureus CVCC 546 gDNA. (A) Gel retardation analysis of the binding of ID13 and DLP4 to S. aureus CVCC 546 gDNA at peptide/gDNA mass ratios of 0, 0.5, 1, 2.5, and 5, respectively. M: λDNA/Hind III marker. (B) Atomic force microscopy (AFM) analysis of the binding of ID13 and DLP4 to S. aureus CVCC 546 gDNA. (C) CD spectra of S. aureus CVCC 546 gDNA at peptide/gDNA mass ratios of 0, 0.5, and 1, respectively.
    Figure Legend Snippet: The binding of ID13 and DLP4 to S. aureus CVCC 546 gDNA. (A) Gel retardation analysis of the binding of ID13 and DLP4 to S. aureus CVCC 546 gDNA at peptide/gDNA mass ratios of 0, 0.5, 1, 2.5, and 5, respectively. M: λDNA/Hind III marker. (B) Atomic force microscopy (AFM) analysis of the binding of ID13 and DLP4 to S. aureus CVCC 546 gDNA. (C) CD spectra of S. aureus CVCC 546 gDNA at peptide/gDNA mass ratios of 0, 0.5, and 1, respectively.

    Techniques Used: Binding Assay, Electrophoretic Mobility Shift Assay, Marker, Microscopy

    (A) Flow cytometric analysis of S. aureus CVCC 546. Cells were treated with 1×, 2×, or 4 × MIC ID13, respectively; cells treated with 2 × MIC DLP4 or vancomycin (Van) and left without treatment were used as the positive and negative control, respectively ( n = 3). (B) The extracellular levels of K + released by S. aureus CVCC 546 cells treated with peptide ID13, DLP4, and nisin, respectively ( n = 3). Statistical significance of differences was determined using (A) one-way and (B) two-way ANOVA followed by Dunnett’s multiple comparison. **** p
    Figure Legend Snippet: (A) Flow cytometric analysis of S. aureus CVCC 546. Cells were treated with 1×, 2×, or 4 × MIC ID13, respectively; cells treated with 2 × MIC DLP4 or vancomycin (Van) and left without treatment were used as the positive and negative control, respectively ( n = 3). (B) The extracellular levels of K + released by S. aureus CVCC 546 cells treated with peptide ID13, DLP4, and nisin, respectively ( n = 3). Statistical significance of differences was determined using (A) one-way and (B) two-way ANOVA followed by Dunnett’s multiple comparison. **** p

    Techniques Used: Negative Control

    (A) SEM and (B) TEM micrographs of S. aureus CVCC 546 treated with ID13, DLP4, or vancomycin (Van) at 4 × MIC for 2 h or left untreated as control. Red arrow: membrane perforation; yellow arrow: cell shrinkage; green arrow: leakage of cytosol; blue arrow: empty regions; cyan arrow: mesosome-like structure; black arrow: cell rupture.
    Figure Legend Snippet: (A) SEM and (B) TEM micrographs of S. aureus CVCC 546 treated with ID13, DLP4, or vancomycin (Van) at 4 × MIC for 2 h or left untreated as control. Red arrow: membrane perforation; yellow arrow: cell shrinkage; green arrow: leakage of cytosol; blue arrow: empty regions; cyan arrow: mesosome-like structure; black arrow: cell rupture.

    Techniques Used: Transmission Electron Microscopy

    The efficacy of peptide ID13 in vitro and in vivo with DLP4 and vancomycin (Van) as positive controls. (A) Time-kill assay of ID13, DLP4, and vancomycin (Van) against S. aureus CVCC 546 ( n = 3). (B) PAEs of ID13, DLP4, and vancomycin (Van) against S. aureus CVCC 546 ( n = 3). (C) Single i.p. treatment with ID13, DLP4, and vancomycin (Van) in the mouse thigh infection model ( n = 6). Effects of ID13, DLP4, and vancomycin (Van) on inflammatory cytokine levels of (D) TNF-α, (E) IL-6, and (F) IL-10. Statistical significance of differences was determined using the two-way ANOVA for (A) and one-way ANOVA for (B–F) , followed by Dunnett’s multiple comparison. (*) indicates the significance between ID13, DLP4, or vancomycin and PBS. ** p
    Figure Legend Snippet: The efficacy of peptide ID13 in vitro and in vivo with DLP4 and vancomycin (Van) as positive controls. (A) Time-kill assay of ID13, DLP4, and vancomycin (Van) against S. aureus CVCC 546 ( n = 3). (B) PAEs of ID13, DLP4, and vancomycin (Van) against S. aureus CVCC 546 ( n = 3). (C) Single i.p. treatment with ID13, DLP4, and vancomycin (Van) in the mouse thigh infection model ( n = 6). Effects of ID13, DLP4, and vancomycin (Van) on inflammatory cytokine levels of (D) TNF-α, (E) IL-6, and (F) IL-10. Statistical significance of differences was determined using the two-way ANOVA for (A) and one-way ANOVA for (B–F) , followed by Dunnett’s multiple comparison. (*) indicates the significance between ID13, DLP4, or vancomycin and PBS. ** p

    Techniques Used: In Vitro, In Vivo, Time-Kill Assay, Infection

    15) Product Images from "An Enhanced Variant Designed From DLP4 Cationic Peptide Against Staphylococcus aureus CVCC 546"

    Article Title: An Enhanced Variant Designed From DLP4 Cationic Peptide Against Staphylococcus aureus CVCC 546

    Journal: Frontiers in Microbiology

    doi: 10.3389/fmicb.2020.01057

    The binding of ID13 and DLP4 to S. aureus CVCC 546 gDNA. (A) Gel retardation analysis of the binding of ID13 and DLP4 to S. aureus CVCC 546 gDNA at peptide/gDNA mass ratios of 0, 0.5, 1, 2.5, and 5, respectively. M: λDNA/Hind III marker. (B) Atomic force microscopy (AFM) analysis of the binding of ID13 and DLP4 to S. aureus CVCC 546 gDNA. (C) CD spectra of S. aureus CVCC 546 gDNA at peptide/gDNA mass ratios of 0, 0.5, and 1, respectively.
    Figure Legend Snippet: The binding of ID13 and DLP4 to S. aureus CVCC 546 gDNA. (A) Gel retardation analysis of the binding of ID13 and DLP4 to S. aureus CVCC 546 gDNA at peptide/gDNA mass ratios of 0, 0.5, 1, 2.5, and 5, respectively. M: λDNA/Hind III marker. (B) Atomic force microscopy (AFM) analysis of the binding of ID13 and DLP4 to S. aureus CVCC 546 gDNA. (C) CD spectra of S. aureus CVCC 546 gDNA at peptide/gDNA mass ratios of 0, 0.5, and 1, respectively.

    Techniques Used: Binding Assay, Electrophoretic Mobility Shift Assay, Marker, Microscopy

    (A) Flow cytometric analysis of S. aureus CVCC 546. Cells were treated with 1×, 2×, or 4 × MIC ID13, respectively; cells treated with 2 × MIC DLP4 or vancomycin (Van) and left without treatment were used as the positive and negative control, respectively ( n = 3). (B) The extracellular levels of K + released by S. aureus CVCC 546 cells treated with peptide ID13, DLP4, and nisin, respectively ( n = 3). Statistical significance of differences was determined using (A) one-way and (B) two-way ANOVA followed by Dunnett’s multiple comparison. **** p
    Figure Legend Snippet: (A) Flow cytometric analysis of S. aureus CVCC 546. Cells were treated with 1×, 2×, or 4 × MIC ID13, respectively; cells treated with 2 × MIC DLP4 or vancomycin (Van) and left without treatment were used as the positive and negative control, respectively ( n = 3). (B) The extracellular levels of K + released by S. aureus CVCC 546 cells treated with peptide ID13, DLP4, and nisin, respectively ( n = 3). Statistical significance of differences was determined using (A) one-way and (B) two-way ANOVA followed by Dunnett’s multiple comparison. **** p

    Techniques Used: Negative Control

    (A) SEM and (B) TEM micrographs of S. aureus CVCC 546 treated with ID13, DLP4, or vancomycin (Van) at 4 × MIC for 2 h or left untreated as control. Red arrow: membrane perforation; yellow arrow: cell shrinkage; green arrow: leakage of cytosol; blue arrow: empty regions; cyan arrow: mesosome-like structure; black arrow: cell rupture.
    Figure Legend Snippet: (A) SEM and (B) TEM micrographs of S. aureus CVCC 546 treated with ID13, DLP4, or vancomycin (Van) at 4 × MIC for 2 h or left untreated as control. Red arrow: membrane perforation; yellow arrow: cell shrinkage; green arrow: leakage of cytosol; blue arrow: empty regions; cyan arrow: mesosome-like structure; black arrow: cell rupture.

    Techniques Used: Transmission Electron Microscopy

    The efficacy of peptide ID13 in vitro and in vivo with DLP4 and vancomycin (Van) as positive controls. (A) Time-kill assay of ID13, DLP4, and vancomycin (Van) against S. aureus CVCC 546 ( n = 3). (B) PAEs of ID13, DLP4, and vancomycin (Van) against S. aureus CVCC 546 ( n = 3). (C) Single i.p. treatment with ID13, DLP4, and vancomycin (Van) in the mouse thigh infection model ( n = 6). Effects of ID13, DLP4, and vancomycin (Van) on inflammatory cytokine levels of (D) TNF-α, (E) IL-6, and (F) IL-10. Statistical significance of differences was determined using the two-way ANOVA for (A) and one-way ANOVA for (B–F) , followed by Dunnett’s multiple comparison. (*) indicates the significance between ID13, DLP4, or vancomycin and PBS. ** p
    Figure Legend Snippet: The efficacy of peptide ID13 in vitro and in vivo with DLP4 and vancomycin (Van) as positive controls. (A) Time-kill assay of ID13, DLP4, and vancomycin (Van) against S. aureus CVCC 546 ( n = 3). (B) PAEs of ID13, DLP4, and vancomycin (Van) against S. aureus CVCC 546 ( n = 3). (C) Single i.p. treatment with ID13, DLP4, and vancomycin (Van) in the mouse thigh infection model ( n = 6). Effects of ID13, DLP4, and vancomycin (Van) on inflammatory cytokine levels of (D) TNF-α, (E) IL-6, and (F) IL-10. Statistical significance of differences was determined using the two-way ANOVA for (A) and one-way ANOVA for (B–F) , followed by Dunnett’s multiple comparison. (*) indicates the significance between ID13, DLP4, or vancomycin and PBS. ** p

    Techniques Used: In Vitro, In Vivo, Time-Kill Assay, Infection

    16) Product Images from "An Enhanced Variant Designed From DLP4 Cationic Peptide Against Staphylococcus aureus CVCC 546"

    Article Title: An Enhanced Variant Designed From DLP4 Cationic Peptide Against Staphylococcus aureus CVCC 546

    Journal: Frontiers in Microbiology

    doi: 10.3389/fmicb.2020.01057

    The binding of ID13 and DLP4 to S. aureus CVCC 546 gDNA. (A) Gel retardation analysis of the binding of ID13 and DLP4 to S. aureus CVCC 546 gDNA at peptide/gDNA mass ratios of 0, 0.5, 1, 2.5, and 5, respectively. M: λDNA/Hind III marker. (B) Atomic force microscopy (AFM) analysis of the binding of ID13 and DLP4 to S. aureus CVCC 546 gDNA. (C) CD spectra of S. aureus CVCC 546 gDNA at peptide/gDNA mass ratios of 0, 0.5, and 1, respectively.
    Figure Legend Snippet: The binding of ID13 and DLP4 to S. aureus CVCC 546 gDNA. (A) Gel retardation analysis of the binding of ID13 and DLP4 to S. aureus CVCC 546 gDNA at peptide/gDNA mass ratios of 0, 0.5, 1, 2.5, and 5, respectively. M: λDNA/Hind III marker. (B) Atomic force microscopy (AFM) analysis of the binding of ID13 and DLP4 to S. aureus CVCC 546 gDNA. (C) CD spectra of S. aureus CVCC 546 gDNA at peptide/gDNA mass ratios of 0, 0.5, and 1, respectively.

    Techniques Used: Binding Assay, Electrophoretic Mobility Shift Assay, Marker, Microscopy

    (A) Flow cytometric analysis of S. aureus CVCC 546. Cells were treated with 1×, 2×, or 4 × MIC ID13, respectively; cells treated with 2 × MIC DLP4 or vancomycin (Van) and left without treatment were used as the positive and negative control, respectively ( n = 3). (B) The extracellular levels of K + released by S. aureus CVCC 546 cells treated with peptide ID13, DLP4, and nisin, respectively ( n = 3). Statistical significance of differences was determined using (A) one-way and (B) two-way ANOVA followed by Dunnett’s multiple comparison. **** p
    Figure Legend Snippet: (A) Flow cytometric analysis of S. aureus CVCC 546. Cells were treated with 1×, 2×, or 4 × MIC ID13, respectively; cells treated with 2 × MIC DLP4 or vancomycin (Van) and left without treatment were used as the positive and negative control, respectively ( n = 3). (B) The extracellular levels of K + released by S. aureus CVCC 546 cells treated with peptide ID13, DLP4, and nisin, respectively ( n = 3). Statistical significance of differences was determined using (A) one-way and (B) two-way ANOVA followed by Dunnett’s multiple comparison. **** p

    Techniques Used: Negative Control

    (A) SEM and (B) TEM micrographs of S. aureus CVCC 546 treated with ID13, DLP4, or vancomycin (Van) at 4 × MIC for 2 h or left untreated as control. Red arrow: membrane perforation; yellow arrow: cell shrinkage; green arrow: leakage of cytosol; blue arrow: empty regions; cyan arrow: mesosome-like structure; black arrow: cell rupture.
    Figure Legend Snippet: (A) SEM and (B) TEM micrographs of S. aureus CVCC 546 treated with ID13, DLP4, or vancomycin (Van) at 4 × MIC for 2 h or left untreated as control. Red arrow: membrane perforation; yellow arrow: cell shrinkage; green arrow: leakage of cytosol; blue arrow: empty regions; cyan arrow: mesosome-like structure; black arrow: cell rupture.

    Techniques Used: Transmission Electron Microscopy

    The efficacy of peptide ID13 in vitro and in vivo with DLP4 and vancomycin (Van) as positive controls. (A) Time-kill assay of ID13, DLP4, and vancomycin (Van) against S. aureus CVCC 546 ( n = 3). (B) PAEs of ID13, DLP4, and vancomycin (Van) against S. aureus CVCC 546 ( n = 3). (C) Single i.p. treatment with ID13, DLP4, and vancomycin (Van) in the mouse thigh infection model ( n = 6). Effects of ID13, DLP4, and vancomycin (Van) on inflammatory cytokine levels of (D) TNF-α, (E) IL-6, and (F) IL-10. Statistical significance of differences was determined using the two-way ANOVA for (A) and one-way ANOVA for (B–F) , followed by Dunnett’s multiple comparison. (*) indicates the significance between ID13, DLP4, or vancomycin and PBS. ** p
    Figure Legend Snippet: The efficacy of peptide ID13 in vitro and in vivo with DLP4 and vancomycin (Van) as positive controls. (A) Time-kill assay of ID13, DLP4, and vancomycin (Van) against S. aureus CVCC 546 ( n = 3). (B) PAEs of ID13, DLP4, and vancomycin (Van) against S. aureus CVCC 546 ( n = 3). (C) Single i.p. treatment with ID13, DLP4, and vancomycin (Van) in the mouse thigh infection model ( n = 6). Effects of ID13, DLP4, and vancomycin (Van) on inflammatory cytokine levels of (D) TNF-α, (E) IL-6, and (F) IL-10. Statistical significance of differences was determined using the two-way ANOVA for (A) and one-way ANOVA for (B–F) , followed by Dunnett’s multiple comparison. (*) indicates the significance between ID13, DLP4, or vancomycin and PBS. ** p

    Techniques Used: In Vitro, In Vivo, Time-Kill Assay, Infection

    17) Product Images from "An Enhanced Variant Designed From DLP4 Cationic Peptide Against Staphylococcus aureus CVCC 546"

    Article Title: An Enhanced Variant Designed From DLP4 Cationic Peptide Against Staphylococcus aureus CVCC 546

    Journal: Frontiers in Microbiology

    doi: 10.3389/fmicb.2020.01057

    The binding of ID13 and DLP4 to S. aureus CVCC 546 gDNA. (A) Gel retardation analysis of the binding of ID13 and DLP4 to S. aureus CVCC 546 gDNA at peptide/gDNA mass ratios of 0, 0.5, 1, 2.5, and 5, respectively. M: λDNA/Hind III marker. (B) Atomic force microscopy (AFM) analysis of the binding of ID13 and DLP4 to S. aureus CVCC 546 gDNA. (C) CD spectra of S. aureus CVCC 546 gDNA at peptide/gDNA mass ratios of 0, 0.5, and 1, respectively.
    Figure Legend Snippet: The binding of ID13 and DLP4 to S. aureus CVCC 546 gDNA. (A) Gel retardation analysis of the binding of ID13 and DLP4 to S. aureus CVCC 546 gDNA at peptide/gDNA mass ratios of 0, 0.5, 1, 2.5, and 5, respectively. M: λDNA/Hind III marker. (B) Atomic force microscopy (AFM) analysis of the binding of ID13 and DLP4 to S. aureus CVCC 546 gDNA. (C) CD spectra of S. aureus CVCC 546 gDNA at peptide/gDNA mass ratios of 0, 0.5, and 1, respectively.

    Techniques Used: Binding Assay, Electrophoretic Mobility Shift Assay, Marker, Microscopy

    (A) Flow cytometric analysis of S. aureus CVCC 546. Cells were treated with 1×, 2×, or 4 × MIC ID13, respectively; cells treated with 2 × MIC DLP4 or vancomycin (Van) and left without treatment were used as the positive and negative control, respectively ( n = 3). (B) The extracellular levels of K + released by S. aureus CVCC 546 cells treated with peptide ID13, DLP4, and nisin, respectively ( n = 3). Statistical significance of differences was determined using (A) one-way and (B) two-way ANOVA followed by Dunnett’s multiple comparison. **** p
    Figure Legend Snippet: (A) Flow cytometric analysis of S. aureus CVCC 546. Cells were treated with 1×, 2×, or 4 × MIC ID13, respectively; cells treated with 2 × MIC DLP4 or vancomycin (Van) and left without treatment were used as the positive and negative control, respectively ( n = 3). (B) The extracellular levels of K + released by S. aureus CVCC 546 cells treated with peptide ID13, DLP4, and nisin, respectively ( n = 3). Statistical significance of differences was determined using (A) one-way and (B) two-way ANOVA followed by Dunnett’s multiple comparison. **** p

    Techniques Used: Negative Control

    (A) SEM and (B) TEM micrographs of S. aureus CVCC 546 treated with ID13, DLP4, or vancomycin (Van) at 4 × MIC for 2 h or left untreated as control. Red arrow: membrane perforation; yellow arrow: cell shrinkage; green arrow: leakage of cytosol; blue arrow: empty regions; cyan arrow: mesosome-like structure; black arrow: cell rupture.
    Figure Legend Snippet: (A) SEM and (B) TEM micrographs of S. aureus CVCC 546 treated with ID13, DLP4, or vancomycin (Van) at 4 × MIC for 2 h or left untreated as control. Red arrow: membrane perforation; yellow arrow: cell shrinkage; green arrow: leakage of cytosol; blue arrow: empty regions; cyan arrow: mesosome-like structure; black arrow: cell rupture.

    Techniques Used: Transmission Electron Microscopy

    The efficacy of peptide ID13 in vitro and in vivo with DLP4 and vancomycin (Van) as positive controls. (A) Time-kill assay of ID13, DLP4, and vancomycin (Van) against S. aureus CVCC 546 ( n = 3). (B) PAEs of ID13, DLP4, and vancomycin (Van) against S. aureus CVCC 546 ( n = 3). (C) Single i.p. treatment with ID13, DLP4, and vancomycin (Van) in the mouse thigh infection model ( n = 6). Effects of ID13, DLP4, and vancomycin (Van) on inflammatory cytokine levels of (D) TNF-α, (E) IL-6, and (F) IL-10. Statistical significance of differences was determined using the two-way ANOVA for (A) and one-way ANOVA for (B–F) , followed by Dunnett’s multiple comparison. (*) indicates the significance between ID13, DLP4, or vancomycin and PBS. ** p
    Figure Legend Snippet: The efficacy of peptide ID13 in vitro and in vivo with DLP4 and vancomycin (Van) as positive controls. (A) Time-kill assay of ID13, DLP4, and vancomycin (Van) against S. aureus CVCC 546 ( n = 3). (B) PAEs of ID13, DLP4, and vancomycin (Van) against S. aureus CVCC 546 ( n = 3). (C) Single i.p. treatment with ID13, DLP4, and vancomycin (Van) in the mouse thigh infection model ( n = 6). Effects of ID13, DLP4, and vancomycin (Van) on inflammatory cytokine levels of (D) TNF-α, (E) IL-6, and (F) IL-10. Statistical significance of differences was determined using the two-way ANOVA for (A) and one-way ANOVA for (B–F) , followed by Dunnett’s multiple comparison. (*) indicates the significance between ID13, DLP4, or vancomycin and PBS. ** p

    Techniques Used: In Vitro, In Vivo, Time-Kill Assay, Infection

    18) Product Images from "An Enhanced Variant Designed From DLP4 Cationic Peptide Against Staphylococcus aureus CVCC 546"

    Article Title: An Enhanced Variant Designed From DLP4 Cationic Peptide Against Staphylococcus aureus CVCC 546

    Journal: Frontiers in Microbiology

    doi: 10.3389/fmicb.2020.01057

    The binding of ID13 and DLP4 to S. aureus CVCC 546 gDNA. (A) Gel retardation analysis of the binding of ID13 and DLP4 to S. aureus CVCC 546 gDNA at peptide/gDNA mass ratios of 0, 0.5, 1, 2.5, and 5, respectively. M: λDNA/Hind III marker. (B) Atomic force microscopy (AFM) analysis of the binding of ID13 and DLP4 to S. aureus CVCC 546 gDNA. (C) CD spectra of S. aureus CVCC 546 gDNA at peptide/gDNA mass ratios of 0, 0.5, and 1, respectively.
    Figure Legend Snippet: The binding of ID13 and DLP4 to S. aureus CVCC 546 gDNA. (A) Gel retardation analysis of the binding of ID13 and DLP4 to S. aureus CVCC 546 gDNA at peptide/gDNA mass ratios of 0, 0.5, 1, 2.5, and 5, respectively. M: λDNA/Hind III marker. (B) Atomic force microscopy (AFM) analysis of the binding of ID13 and DLP4 to S. aureus CVCC 546 gDNA. (C) CD spectra of S. aureus CVCC 546 gDNA at peptide/gDNA mass ratios of 0, 0.5, and 1, respectively.

    Techniques Used: Binding Assay, Electrophoretic Mobility Shift Assay, Marker, Microscopy

    (A) Flow cytometric analysis of S. aureus CVCC 546. Cells were treated with 1×, 2×, or 4 × MIC ID13, respectively; cells treated with 2 × MIC DLP4 or vancomycin (Van) and left without treatment were used as the positive and negative control, respectively ( n = 3). (B) The extracellular levels of K + released by S. aureus CVCC 546 cells treated with peptide ID13, DLP4, and nisin, respectively ( n = 3). Statistical significance of differences was determined using (A) one-way and (B) two-way ANOVA followed by Dunnett’s multiple comparison. **** p
    Figure Legend Snippet: (A) Flow cytometric analysis of S. aureus CVCC 546. Cells were treated with 1×, 2×, or 4 × MIC ID13, respectively; cells treated with 2 × MIC DLP4 or vancomycin (Van) and left without treatment were used as the positive and negative control, respectively ( n = 3). (B) The extracellular levels of K + released by S. aureus CVCC 546 cells treated with peptide ID13, DLP4, and nisin, respectively ( n = 3). Statistical significance of differences was determined using (A) one-way and (B) two-way ANOVA followed by Dunnett’s multiple comparison. **** p

    Techniques Used: Negative Control

    (A) SEM and (B) TEM micrographs of S. aureus CVCC 546 treated with ID13, DLP4, or vancomycin (Van) at 4 × MIC for 2 h or left untreated as control. Red arrow: membrane perforation; yellow arrow: cell shrinkage; green arrow: leakage of cytosol; blue arrow: empty regions; cyan arrow: mesosome-like structure; black arrow: cell rupture.
    Figure Legend Snippet: (A) SEM and (B) TEM micrographs of S. aureus CVCC 546 treated with ID13, DLP4, or vancomycin (Van) at 4 × MIC for 2 h or left untreated as control. Red arrow: membrane perforation; yellow arrow: cell shrinkage; green arrow: leakage of cytosol; blue arrow: empty regions; cyan arrow: mesosome-like structure; black arrow: cell rupture.

    Techniques Used: Transmission Electron Microscopy

    The efficacy of peptide ID13 in vitro and in vivo with DLP4 and vancomycin (Van) as positive controls. (A) Time-kill assay of ID13, DLP4, and vancomycin (Van) against S. aureus CVCC 546 ( n = 3). (B) PAEs of ID13, DLP4, and vancomycin (Van) against S. aureus CVCC 546 ( n = 3). (C) Single i.p. treatment with ID13, DLP4, and vancomycin (Van) in the mouse thigh infection model ( n = 6). Effects of ID13, DLP4, and vancomycin (Van) on inflammatory cytokine levels of (D) TNF-α, (E) IL-6, and (F) IL-10. Statistical significance of differences was determined using the two-way ANOVA for (A) and one-way ANOVA for (B–F) , followed by Dunnett’s multiple comparison. (*) indicates the significance between ID13, DLP4, or vancomycin and PBS. ** p
    Figure Legend Snippet: The efficacy of peptide ID13 in vitro and in vivo with DLP4 and vancomycin (Van) as positive controls. (A) Time-kill assay of ID13, DLP4, and vancomycin (Van) against S. aureus CVCC 546 ( n = 3). (B) PAEs of ID13, DLP4, and vancomycin (Van) against S. aureus CVCC 546 ( n = 3). (C) Single i.p. treatment with ID13, DLP4, and vancomycin (Van) in the mouse thigh infection model ( n = 6). Effects of ID13, DLP4, and vancomycin (Van) on inflammatory cytokine levels of (D) TNF-α, (E) IL-6, and (F) IL-10. Statistical significance of differences was determined using the two-way ANOVA for (A) and one-way ANOVA for (B–F) , followed by Dunnett’s multiple comparison. (*) indicates the significance between ID13, DLP4, or vancomycin and PBS. ** p

    Techniques Used: In Vitro, In Vivo, Time-Kill Assay, Infection

    Similar Products

  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 95
    ATCC s aureus cvcc 546
    The effects of peptide ID13 on S. aureus . a The membrane depolarization, b differential gene expression, c enriched GO terms, and d KEGG pathway of ID13-treated S. aureus <t>CVCC</t> 546
    S Aureus Cvcc 546, supplied by ATCC, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/s aureus cvcc 546/product/ATCC
    Average 95 stars, based on 1 article reviews
    Price from $9.99 to $1999.99
    s aureus cvcc 546 - by Bioz Stars, 2022-11
    95/100 stars
      Buy from Supplier

    Image Search Results


    The effects of peptide ID13 on S. aureus . a The membrane depolarization, b differential gene expression, c enriched GO terms, and d KEGG pathway of ID13-treated S. aureus CVCC 546

    Journal: Applied Microbiology and Biotechnology

    Article Title: Therapeutic potential of a designed CSαβ peptide ID13 in Staphylococcus aureus-induced endometritis of mice

    doi: 10.1007/s00253-020-10685-x

    Figure Lengend Snippet: The effects of peptide ID13 on S. aureus . a The membrane depolarization, b differential gene expression, c enriched GO terms, and d KEGG pathway of ID13-treated S. aureus CVCC 546

    Article Snippet: Effects of peptide ID13 on S. aureus CVCC 546

    Techniques: Expressing

    In vitro efficacy of peptide ID13.  a  Combined application of peptide ID13 with antibiotics against  S. aureus  CVCC 546, vancomycin, ampicillin, rifampin, and ciprofloxacin that are represented by Van, Amp, Rif, and Cip, respectively, and  b  antimicrobial activity against intracellular  S. aureus  CVCC 546. Inhibition of LTA-induced cytokines  c  TNF-α,  d  IL-1β,  e  IL-6, and  f  IL-10 from RAW 264.7. Statistical significance of differences between experimental and LTA groups were determined using the one-way ANOVA and Dunnett’s multiple comparison. * p

    Journal: Applied Microbiology and Biotechnology

    Article Title: Therapeutic potential of a designed CSαβ peptide ID13 in Staphylococcus aureus-induced endometritis of mice

    doi: 10.1007/s00253-020-10685-x

    Figure Lengend Snippet: In vitro efficacy of peptide ID13. a Combined application of peptide ID13 with antibiotics against S. aureus CVCC 546, vancomycin, ampicillin, rifampin, and ciprofloxacin that are represented by Van, Amp, Rif, and Cip, respectively, and b antimicrobial activity against intracellular S. aureus CVCC 546. Inhibition of LTA-induced cytokines c TNF-α, d IL-1β, e IL-6, and f IL-10 from RAW 264.7. Statistical significance of differences between experimental and LTA groups were determined using the one-way ANOVA and Dunnett’s multiple comparison. * p

    Article Snippet: Effects of peptide ID13 on S. aureus CVCC 546

    Techniques: In Vitro, Activity Assay, Inhibition